Drugs / AVZO-023
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06998407 | Aug 2025 → Aug 2028 expected | hormone receptor-positive breast cancer | Avenzo Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVZO-023 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06998407 ↗ |
| Action | Inhibit | “AVZO-023 is an oral selective CDK4 inhibitor” NCT06998407 ↗ |
| Route | Oral | “AVZO-023 is an oral selective CDK4 inhibitor” NCT06998407 ↗ |
| Target | CDK4 | “AVZO-023 is an oral selective CDK4 inhibitor” NCT06998407 ↗ |